Sarcopenia and long-term survival outcomes after local therapy for colorectal liver metastasis: a meta-analysis.


Journal

HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921

Informations de publication

Date de publication:
01 2022
Historique:
received: 10 06 2021
revised: 28 07 2021
accepted: 16 08 2021
pubmed: 25 9 2021
medline: 6 4 2022
entrez: 24 9 2021
Statut: ppublish

Résumé

Sarcopenia is defined as either low pre-operative muscle mass or low muscle density on abdominal CT imaging. It has been associated with worse short-term outcomes after surgery for colorectal liver metastases. This study aimed to evaluate whether sarcopenia also impacts long-term survival outcomes in these patients. A random-effects meta-analysis was conducted following the PRISMA guidelines. Overall survival (OS) and disease-free survival (DFS) outcomes were evaluated. Eleven studies were included, ten reporting on the impact of low muscle mass and four on low muscle density. Sample sizes ranged between 47 and 539 (2124 patients in total). Altogether, 897 (42%) patients were considered sarcopenic, although definitions varied between studies. Median follow-up was 21-74 months. Low muscle mass (hazard ration (HR) 1.35, 95%CI 1.08-1.68) and low muscle density (HR 1.97, 95%CI 1.07-3.62) were associated with impaired OS. Low muscle mass (pooled HR 1.17, 95%CI 0.94-1.46) and low muscle density (pooled HR 1.13, 95%CI 0.85-1.50) were not associated with impaired RFS. Sarcopenia is associated with poorer OS, but not RFS, in patients with CRLM. Additional studies with standardized sarcopenia definitions are needed to better assess the impact of sarcopenia in patients with CRLM.

Sections du résumé

BACKGROUND
Sarcopenia is defined as either low pre-operative muscle mass or low muscle density on abdominal CT imaging. It has been associated with worse short-term outcomes after surgery for colorectal liver metastases. This study aimed to evaluate whether sarcopenia also impacts long-term survival outcomes in these patients.
METHODS
A random-effects meta-analysis was conducted following the PRISMA guidelines. Overall survival (OS) and disease-free survival (DFS) outcomes were evaluated.
RESULTS
Eleven studies were included, ten reporting on the impact of low muscle mass and four on low muscle density. Sample sizes ranged between 47 and 539 (2124 patients in total). Altogether, 897 (42%) patients were considered sarcopenic, although definitions varied between studies. Median follow-up was 21-74 months. Low muscle mass (hazard ration (HR) 1.35, 95%CI 1.08-1.68) and low muscle density (HR 1.97, 95%CI 1.07-3.62) were associated with impaired OS. Low muscle mass (pooled HR 1.17, 95%CI 0.94-1.46) and low muscle density (pooled HR 1.13, 95%CI 0.85-1.50) were not associated with impaired RFS.
DISCUSSION
Sarcopenia is associated with poorer OS, but not RFS, in patients with CRLM. Additional studies with standardized sarcopenia definitions are needed to better assess the impact of sarcopenia in patients with CRLM.

Identifiants

pubmed: 34556406
pii: S1365-182X(21)01591-4
doi: 10.1016/j.hpb.2021.08.947
pii:
doi:

Types de publication

Journal Article Meta-Analysis Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

9-16

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Ruben B Waalboer (RB)

Department of Surgical Oncology and Gastro-intestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Yannick M Meyer (YM)

Department of Surgical Oncology and Gastro-intestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Boris Galjart (B)

Department of Surgical Oncology and Gastro-intestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Pim B Olthof (PB)

Department of Surgical Oncology and Gastro-intestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Jeroen L A van Vugt (JLA)

Department of Surgical Oncology and Gastro-intestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Dirk J Grünhagen (DJ)

Department of Surgical Oncology and Gastro-intestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Cornelis Verhoef (C)

Department of Surgical Oncology and Gastro-intestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: c.verhoef@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH